All In Biotech

Drug Trial Radar · NCT03102606

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

A Phase 3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)

Last checked: Nov 19, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

May 29, 2018

Primary completion

Dec 12, 2018

Study completion Feb 8, 2021

Sponsor

Sponsor type
Industry
Collaborators
Covance; ICON plc
First posted
Apr 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess Duration of Severe Neutropenia (DSN) in treatment Cycle 1 in patients with advanced or metastatic breast cancer, who have failed \>/= 1 but \< 5 prior lines of chemotherapy; locally advanced or metastatic non small cell lung cancer (NSCLC) after platinum therapy failure; or hormone refractory (androgen independent) metastatic prostate cancer treated with docetaxel (75 mg/m2) + plinabulin (40 mg) versus docetaxel (75 mg/m2) + pegfilgrastim (6 mg). Neutrophils count will be assessed at baseline; Pre dose during Cycle 1, Day 1, 2, 6, 7, 8, 9, 10, 15. \*Study is officially closed on 08 Feb 2021\*

Conditions

  • Chemotherapy-induced Neutropenia

Interventions

  • PlinabulinDrug

    Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).

  • PegfilgrastimDrug

    PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.

  • Saline PlaceboOther

    Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration

  • D5W PlaceboOther

    Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Duration of Severe Neutropenia (DSN)Time frame: 21 Days

Locations

18 sites in 4 countries. Site status is shown where the registry gives one.

  • Stanford University School of Medicine - Cancer Institute

    Stanford, California

  • Hematology/Oncology of the North Shore

    Skokie, Illinois

  • Norton Cancer Institute

    Louisville, Kentucky

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China

  • Linyi Cancer Hospital

    Linyi, China

  • Liaoning Cancer Hospital & Institute

    Shenyang, China

  • Henan Cancer Hospital

    Zhengzhou, China

  • Heilongjiang Cancer Hospital

    Harbin, Heilongjiang, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, China

  • State Budgetary Healthcare Institution of Stavropol Territory "Pyatigorsk Interregional Oncology Dispensary"

    Pyatigorsk, Russia

  • SBI of Healthcare "Oncology Dispensary #2" Ministry of Healthcare of Krasnodar Region

    Sochi, Russia

  • Volgograd Regional Clinical Oncology Dispensary

    Volgograd, Russia

  • Dnipropetrovsk City Multifunctional Hospital

    Dnipro, Ukraine

  • Prykarpatskiy Regional Oncological Center

    Ivano-Frankivsk, Ukraine

  • Communal Institution of Kherson Regional Council "Kherson regional oncological dispensary"

    Kherson, Ukraine

  • Kryvyi Rih Oncology Dispensary

    Kryvyi Rih, Ukraine

  • Lviv State Oncological Regional Treatment and Preventive Center

    Lviv, Ukraine

  • Municipal Institution "Sumy Regional Clinical Oncology Dispensary"

    Sumy, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.